title: Abacavir rechallenge has to be avoided in case of hypersensitivity reaction.
authors.forename: L
authors.initials: L
authors.lastname: Escaut
authors.forename: J Y
authors.initials: JY
authors.lastname: Liotier
authors.forename: E
authors.initials: E
authors.lastname: Albengres
authors.forename: N
authors.initials: N
authors.lastname: Cheminot
authors.forename: D
authors.initials: D
authors.lastname: Vittecoq
mesh_terms: D000707:Anaphylaxis / Q000139:chemically induced*; D015224:Dideoxynucleosides / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000209:etiology*; D004359:Drug Therapy, Combination; D017809:Fatal Outcome; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D019888:Nelfinavir / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D000099227:Abacavir
chemical_list: D015224:Dideoxynucleosides; D017320:HIV Protease Inhibitors; D019888:Nelfinavir; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir